黑人种族与前列腺癌特异性死亡及其他原因死亡的相关性
该多队列研究纳入SEER、VA及RCT三个队列共306100例临床T1-4N0-1M0前列腺癌患者,经逆概率加权调整后,黑人种族在前列腺癌特异性死亡率上未见分期对分期的劣势,但其他原因死亡风险显著增加。
要点
- SEER队列年龄调整后黑人种族前列腺癌特异性死亡风险升高(sHR 1.30)。
- IPW调整后黑人种族10年前列腺癌特异性死亡率增加0.5%,高危组无显著差异。
- VA和RCT队列IPW调整后黑人种族前列腺癌特异性死亡无显著差异或更低。
核心结论
- 调整非生物学差异(尤其是就医可及性和标准化治疗)后,黑人种族似乎与分期对分期的前列腺癌特异性死亡率劣势无关。
- 非转移性前列腺癌黑人男性的其他原因死亡仍存在巨大差异。
研究设计与样本
- 多队列研究,纳入SEER(n=296273)、VA(n=3972)和4项RCT汇总(n=5854)共306100例临床T1-4N0-1M0前列腺癌患者的个体数据。
- 数据收集时间为1992年1月1日至2013年12月31日,分析时间为2017年4月27日至2019年4月13日。
- VA和RCT队列患者分别接受根治性手术和放疗,SEER队列接受根治性治疗、激素治疗或保守管理。
- 采用逆概率加权(IPW)调整人口学、肿瘤和治疗相关基线差异。
主要发现
- SEER队列中,黑人种族与年龄调整的前列腺癌特异性死亡风险升高相关(sHR 1.30;95%CI 1.23-1.37;P<.001)。
- SEER队列IPW调整后,黑人种族与诊断后10年前列腺癌特异性死亡率增加0.5%(95%CI 0.2%-0.9%)相关(sHR 1.09;95%CI 1.04-1.15;P<.001),高危男性无显著差异(sHR 1.04;95%CI 0.97-1.12;P=.29)。
- VA队列IPW调整后前列腺癌特异性死亡无显著差异(sHR 0.85;95%CI 0.56-1.30;P=.46)。
- RCT队列IPW调整后黑人男性风险显著更低(sHR 0.81;95%CI 0.66-0.99;P=.04)。
- 黑人男性其他原因死亡风险在SEER队列(sHR 1.30;95%CI 1.27-1.34;P<.001)和RCT队列(sHR 1.17;95%CI 1.06-1.29;P=.002)IPW调整后均显著增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Black men are more likely to die of prostate cancer than white men. In men with similar stages of disease, the contribution of biological vs nonbiological differences to this observed disparity is unclear. OBJECTIVE: To quantify the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This multiple-cohort study included updated individual patient-level data of men with clinical T1-4N0-1M0 prostate cancer from the following 3 cohorts: Surveillance, Epidemiology, and End Results (SEER [n = 296 273]); 5 equal-access regional medical centers within the Veterans Affairs health system (VA [n = 3972]); and 4 pooled National Cancer Institute-sponsored Radiation Therapy Oncology Group phase 3 randomized clinical trials (RCTs [n = 5854]). Data were collected in the 3 cohorts from January 1, 1992, through December 31, 2013, and analyzed from April 27, 2017, through April 13, 2019. EXPOSURES: In the VA and RCT cohorts, all patients received surgery and radiotherapy, respectively, with curative intent. In SEER, radical treatment, hormone therapy, or conservative management were received. MAIN OUTCOMES AND MEASURES: Prostate cancer-specific mortality (PCSM). Secondary measures included other-cause mortality (OCM). To adjust for demographic-, cancer-, and treatment-related baseline differences, inverse probability weighting (IPW) was performed. RESULTS: Among the 306 100 participants included in the analysis (mean [SD] age, 64.9 [8.9] years), black men constituted 52 840 patients (17.8%) in the SEER cohort, 1513 (38.1%) in the VA cohort, and 1129 (19.3%) in the RCT cohort. Black race was associated with an increased age-adjusted PCSM hazard (subdistribution hazard ratio [sHR], 1.30; 95% CI, 1.23-1.37; P < .001) within the SEER cohort. After IPW adjustment, black race was associated with a 0.5% (95% CI, 0.2%-0.9%) increase in PCSM at 10 years after diagnosis (sHR, 1.09; 95% CI, 1.04-1.15; P < .001), with no significant difference for high-risk men (sHR, 1.04; 95% CI, 0.97-1.12; P = .29). No significant differences in PCSM were found in the VA IPW cohort (sHR, 0.85; 95% CI, 0.56-1.30; P = .46), and black men had a significantly lower hazard in the RCT IPW cohort (sHR, 0.81; 95% CI, 0.66-0.99; P = .04). Black men had a significantly increased hazard of OCM in the SEER (sHR, 1.30; 95% CI, 1.27-1.34; P < .001) and RCT (sHR, 1.17; 95% CI, 1.06-1.29; P = .002) IPW cohorts. CONCLUSIONS AND RELEVANCE: In this study, after adjustment for nonbiological differences, notably access to care and standardized treatment, black race did not appear to be associated with inferior stage-for-stage PCSM. A large disparity remained in OCM for black men with nonmetastatic prostate cancer.
引用
- Dess RT, Hartman HE, Mahal BA, et al. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019. PMID: 31120534. doi:10.1001/jamaoncol.2019.0826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。